ArticleFrontiers in immunology2026

Abrocitinib and dupilumab bridging therapy for bullous pemphigoid with insufficient response to initial corticosteroid therapy: a case report.

Hongchan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.